Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The January 2003 monograph topics are ezetimibe, enfurvitide, aripiprazole, atomoxetine, and amoxicillin/clavulanate potassium extended-release tablets. The DUE is on ezetimibe.
Get full access to this article
View all access options for this article.
References
1.
Hepsera package literature.Gilead Sciences, Inc.; September 2002.
2.
FDA panel rejects Gilead drug for resistant HIV.Reuters Health. November 1, 1999. www.reutershealth.com. Accessed on November 2, 1999.
3.
Gilead halts adefovir dipivoxil development as HIV therapy.Reuters Health. December 7, 1999. www.reutershealth.com. Accessed on December 7, 1999.
4.
Barditch-CrovoP.Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis.1997; 176: 406–13.
5.
De ClercqE.Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology.1997; 40: 295–303.
6.
MillerM.D.Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis.1999; 179: 92–100.
7.
DeeksS.G.The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial. J Infect Dis.1997; 176: 1517–23.
8.
YingC.Lamivudine, adefovir and tenofovir exhibit long-lasting antihepatitis B virus activity in cell culture. J Viral Hepat.2000; 7: 79–83.
9.
JulanderJ.G.Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res.2002; 55: 27–40.
10.
CullenJ.M.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother.2001; 45: 2740–5.
11.
TsiangM.Dynamics of hepatitis B virus clearance from the serum of patients treated with adefovir dipivoxil for 12 weeks [abstract]. Hepatology.1998; 28(4, pt 2): 492A.
12.
TsiangM.Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology.1999; 29: 1863–9.
13.
ColledgeD.In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother.2000; 44: 551–60.
14.
YangH.Lack of emerging resistance mutations in 467 HBeAg–and HBeAg+ patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks [abstract]. J Hepatol.2002; 36(suppl): 137–8.
15.
MarcellinP.Adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B [abstract]. Gastroenterology.2002; 123(1, suppl): 70.
16.
WestlandC.Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy [abstract]. J Hepatol.2002; 36(suppl): 7.
17.
YangH.Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks [abstract]. Hepatology.2001; 34(4, pt 2): 316A.
18.
YangH.Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks [abstract]. Hepatology.2002; 36: 464–73.
19.
XiongX.Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology.1998; 28: 1669–73.
20.
Ono-NitaS.K.Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest.1999; 103: 1635–40.
21.
YingC.Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat.2000; 7: 161–5.
22.
CundyK.C.Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother.1995; 39: 2401–5.
23.
CundyK.C.Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet.1999; 36: 127–43.
24.
BirnkrantD., GoldbergerM.Briefing document for NDA 21–449: Adefovir dipivoxil. Food and Drug Administration. July 10, 2002. www.fda.gov. Accessed August 26, 2002.
25.
KearneyB.Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects [abstract]. J Hepatol.2002; 36(suppl): 100.
26.
HadziyannisS.GS-98–438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48-week results [abstract]. J Hepatol.2002; 36(suppl): 4.
27.
MarcellinP.Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil [abstract]. J Hepatol.2002; 36(suppl): 8.
28.
MarcellinP.Baseline ALT predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV) [abstract]. J Hepatol.2002; 36(suppl): 122.
29.
MarcellinP.GS-98–437 A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results [abstract]. Hepatology.2001; 34(4, pt 2): 340A.
30.
GilsonR.I.Adefovir dipivoxil (bis-POM PMEA) treatment for chronic hepatitis B infection: A placebo-controlled phase I/II study [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15–18, 1996; New Orleans, LA; LB01.
31.
GilsonR.J.A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatitis.1999; 6: 387–95.
32.
GilsonR.J.Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection [abstract]. Hepatology.1998; 28(4, pt 2): 491A.
33.
HeathcoteE.J.Suppression of serum HBV DNA and reduction in serum amino transferase levels following 12 weeks of adefovir dipivoxil therapy in chronic hepatitis B patients with HBeAg(–)/anti-HBe(+)/HBV DNA(+) HBV infection [abstract]. Hepatology.2000; 32(4, pt 2): 586A.
34.
HeathcoteE.J.Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients [abstract]. Hepatology.2001; 34(4, pt 2): 316A.
35.
PetersM.Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis [abstract]. J Hepatol.2002; 36(suppl): 6.
36.
PerilloR.The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine — preliminary 24 week results [abstract]. Hepatology.2001; 34(4, pt 2): 349A.
37.
PerilloR.Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology.2000; 32: 129–34.
38.
BenhamouY.Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients [abstract]. J Hepatol.2002; 36(suppl): 138.
39.
BenhamouY.Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet.2001; 358: 718–23.
40.
PetersM.Adefovir dipivoxil (ADV) demonstrates anti-viral efficacy and clinical benefit in the treatment of lamivudine resistant (LAM-R) chronic HBV: An analysis of four clinical trials [abstract]. Gastroenterology.2002; 123(1, suppl): 71.
41.
MutimerD.Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: Rapid resolution during treatment with adefovir. Gut.2001; 49: 860–3.
42.
WalshK.M.Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut.2001; 49: 436–40.
43.
PetersM.G.Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation.1999; 68: 1912–4.
44.
AhmadJ.Adefovir dipivoxil suppresses lamivudine resistant hepatitis B virus in liver transplant recipients [abstract]. Hepatology.2000; 32(4, pt 2): 292A.
45.
FisherE.Placebo (PLC)-controlled, multicenter trial of adefovir dipivoxil (ADV) in patients (Pt) with HIV disease [abstract]. Sixth Conference on Retroviruses and Opportunistic Infections. January 31–February 4, 1999; Chicago, IL; 491.
46.
FisherE.Safety of adefovir dipivoxil (ADV) and incidence of proximal renal tubular disorder (PRTD) in a placebo (PLC)-controlled trial in patients (Pt) with advanced HIV disease [abstract]. Sixth Conference on Retroviruses and Opportunistic Infections. January 31– February 4, 1999; Chicago, IL, 678.
47.
KahnJ.A multicenter, randomized, double-blind placebo controlled study of the efficacy and safety of adefovir dipivoxil (Adv) when added to standard antiretroviral therapy (Art) [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 24–27, 1998; San Diego, CA; I-108.
48.
GallantJ.E.The new drugs and how to use them. Hopkins HIV Report.1999; 11(1): 2, 7.
49.
BrosgartC.Serum carnitine levels in AIDS patients with advanced HIV disease from the CPCRA 039 trial [abstract]. Twelfth World AIDS Conference. June 28–July 3, 1998; Geneva, Switzerland; 60508.
50.
NuessleS.J.The Preveon expanded access program: Safety of adefovir dipivoxil (ADV) in antiretroviral treatment experienced patients with advanced HIV disease [abstract]. Sixth Conference on Retroviruses and Opportunistic Infections. January 31– February 4, 1999; Chicago, IL; 379.
51.
BarriereS.Safety of adefovir dipivoxil in the treatment of HIV infection [abstract]. Twelfth World AIDS Conference. June 28–July 3, 1998; Geneva, Switzerland; 12386.
52.
AcostaE.P.Pharmacokinetic (PK) evaluation of saquinavir soft gel capsules (SQV)/ritonavir (RTV) or SQV/nelfinavir (NFV) in combination with delavirdine (DLV) and/or adefovir dipivoxil (ADV)-ACTG 359 [abstract]. Sixth Conference on Retroviruses and Opportunistic Infections. January 31–February 4, 1999; Chicago, IL; 365.
53.
KearneyB.A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen and trimethoprim/sulfamethoxazole [abstract]. J Hepatol.2002; 36(suppl): 100.
